Literature DB >> 20402996

Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-addicted infants.

Urs Zimmermann-Baer1, Ursula Nötzli, Katharina Rentsch, Hans Ulrich Bucher.   

Abstract

OBJECTIVE: The neonatal abstinence scoring system proposed by Finnegan is used widely in neonatal units to initiate and to guide therapy in babies of opiate-dependent mothers. The purpose of this study was to assess the variability of the scores in newborns and infants not exposed to opiates during the first 3 days of life and during 3 consecutive days in weeks 5 or 6. PATIENTS AND METHODS: Healthy neonates born after 34 completed weeks of gestation, whose parents denied opiate consumption and gave informed consent, were included in this observational study. Infants with signs or symptoms of disease or with feeding problems were excluded. A modified scoring system was used every 8 hours during 72 hours by trained nurses; 102 neonates were observed for the first 3 days of life and 26 neonates in weeks 5-6. A meconium sample and a urine sample at weeks 5-6 were stored from all infants to be analysed for drugs when the baby scored high. Given a non-Gaussian distribution the scores were represented as percentiles.
RESULTS: During the first 3 days of life median scores remained stable at 2 but the variability increased, with the 95th percentile rising from 5.5 on day 1 to 7 on day 2. At weeks 5-6 median values were higher during daytime (50th percentile = 5, 95th percentile = 8) than night-time (50th percentile = 2, 95th percentile = 6, P = 0.02).
CONCLUSION: Scores increase from days 1-3 to weeks 5-6 and show day-night cycles with 5-6 weeks. Values above 8 can be considered pathological. This data may help to raise suspicion of narcotic withdrawal and to guide therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20402996     DOI: 10.1111/j.1360-0443.2009.02802.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  22 in total

Review 1.  Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Authors:  A K Mangat; G M Schmölzer; W K Kraft
Journal:  Semin Fetal Neonatal Med       Date:  2019-02-05       Impact factor: 3.926

2.  Neonatal adaptation following intrauterine antidepressant exposure: assessment, drug assay levels, and infant development outcomes.

Authors:  Megan Galbally; Olav Spigset; Andrew R Johnson; Rolland Kohan; Martha Lappas; Andrew J Lewis
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

Review 3.  Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant.

Authors:  Davida M Schiff; Matthew R Grossman
Journal:  Semin Fetal Neonatal Med       Date:  2019-01-28       Impact factor: 3.926

4.  Withdrawal syndrome and hypomagnesaemia and in a newborn exposed to valproic acid and carbamazepine during pregnancy.

Authors:  Mehmet Satar; Kadir Ortaköylü; İnci Batun; Hacer Y Yıldızdaş; Ferda Özlü; Hüsnü Demir; Ali Kemal Topaloğlu
Journal:  Turk Pediatri Ars       Date:  2016-06-01

5.  The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.

Authors:  Christine Kreitinger; Hilda Gutierrez; Ajna Hamidovic; Cheryl Schmitt; Preeyaporn Sarangarm; William F Rayburn; Lawrence Leeman; Ludmila N Bakhireva
Journal:  J Matern Fetal Neonatal Med       Date:  2015-03-23

6.  Short- and long-term complications of in utero exposure to lamotrigine.

Authors:  Merav Cohen-Israel; Itai Berger; Einat Y Martonovich; Gil Klinger; Bracha Stahl; Nehama Linder
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

7.  A Quality Improvement Initiative to Increase Scoring Consistency and Accuracy of the Finnegan Tool: Challenges in Obtaining Reliable Assessments of Drug Withdrawal in Neonatal Abstinence Syndrome.

Authors:  Wendy Timpson; Cheryl Killoran; Louise Maranda; Alan Picarillo; Elisabeth Bloch-Salisbury
Journal:  Adv Neonatal Care       Date:  2018-02       Impact factor: 1.968

8.  Analysis of the factors that influence the Finnegan Neonatal Abstinence Scoring System.

Authors:  E Gomez-Pomar; A Christian; L Devlin; K T Ibonia; V A Concina; H Bada; P M Westgate
Journal:  J Perinatol       Date:  2017-04-06       Impact factor: 2.521

Review 9.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

Review 10.  Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant.

Authors:  Walter K Kraft; Megan W Stover; Jonathan M Davis
Journal:  Semin Perinatol       Date:  2016-01-12       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.